Evidence map›Paper›PMID 42251767›Full record

Observational studyDiabetes care2026

Early Pregnancy Glycemic Testing for Prediction of Gestational Diabetes Mellitus and Large-for-Gestational-Age Birth Weight.

GO MOMs Study Group*

Abstract readObservational Study
In one paragraph

Observational study in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

GO MOMs Study Group*

Funding

Glycemic Profile of Pregnancy Consortium Biostatistics Research CenterU01DK123759 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHOLTENS, DENISE M · 2019 to 2025
$17.0M
Measuring Early Pregnancy Glycemia and Its Impact on Adverse OutcomesU01DK123795 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI POWE, CAMILLE ELISE · 2019 to 2024
$4.1M
Comparing Glycemic Profiles in Pregnancy and Maternal and Child Health OutcomesU01DK123783 · NIDDK · WOMEN AND INFANTS HOSPITAL-RHODE ISLAND · PI WERNER, ERIKA F · 2019 to 2024
$3.3M
ChartGlucose4Moms: Characterizing, by Trimester, Continuous Glucose Monitoring Measurements for determining effects on Maternal & Offspring Metabolic SequelaeU01DK123791 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI LEBLANC, ERIN S, VESCO, KIMBERLY KRISTINE · 2019 to 2024
$3.2M
eMOM: enhanced Monitoring to Optimize Maternal Diabetes detectionU01DK123799 · NIDDK · YALE UNIVERSITY · PI MERRIAM, AUDREY, SHERR, JENNIFER LYNN · 2019 to 2024
$3.1M
Glycemic Profiles and Pregnancy Outcomes Study (GLOSS)U01DK123745 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LOWE, WILLIAM L, YEE, LYNN M · 2019 to 2024
$2.9M
NIDDK NIH HHS U01 DK123745NIDDK NIH HHS U01DK123745NIDDK NIH HHS U01 DK123759NIDDK NIH HHS U01DK123759NIDDK NIH HHS U01 DK123783NIDDK NIH HHS U01DK123783NIDDK NIH HHS U01 DK123791NIDDK NIH HHS U01DK123791NIDDK NIH HHS U01 DK123795NIDDK NIH HHS U01DK123795NIDDK NIH HHS U01 DK123799NIDDK NIH HHS U01DK123799
6 · The paper itself

Abstract

objectiveWe evaluated whether early pregnancy oral glucose tolerance testing (OGTT) or continuous glucose monitoring (CGM) improves gestational diabetes mellitus (GDM) or large-for-gestational-age (LGA) birth prediction over clinical factors alone. RESEARCH DESIGN AND

methodsIn the Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMs) study, a prospective observational study at nine U.S. sites (2021-2025), participants with singleton gestation and without preexisting diabetes underwent blinded 75-g OGTT and CGM at 10-14 weeks' gestation. Predictive models for GDM at 24-28 weeks and LGA were developed using these data and clinical factors (maternal age, BMI, GDM or macrosomia history). New glycemic criteria maximized the area under the receiver operating characteristic curve in training data from four sites and were validated in five. Models incorporating OGTT or CGM criteria versus clinical factors alone compared positive predictive value (PPV) at a prespecified negative predictive value (NPV) at a reported 8.3% national GDM prevalence and 10% for LGA.

resultsOf 2,178 participants, 93.3% who were pregnant at 24-28 weeks completed OGTTs (15.4% GDM), and 98.1% with live births had data to determine LGA (11.2% LGA). At NPV ≥96% and 8.3% GDM prevalence, PPV for GDM was 12.2% (95% CI 11.0-13.3%) for clinical factors alone, 26.5% (23.1-30.3%) for OGTT plus clinical factors, and 19.8% (17.2-22.5%) for CGM plus clinical factors. For LGA, neither glycemic model improved PPV. Validation confirmed findings.

conclusionsIn a U.S.-representative population, adding 10- to 14-week OGTT or CGM criteria to clinical factors improved GDM but not LGA prediction. Future studies should determine whether predicting GDM in the first trimester facilitates interventions that improve GDM-related pregnancy outcomes.

Indexed as

Birth WeightDiabetes, GestationalAdultBlood GlucoseContinuous Glucose MonitoringFemaleGlucose Tolerance TestHumansInfant, Large for Gestational AgeInfant, NewbornPregnancyProspective StudiesBlood Glucose

Identifiers

PMID42251767
PMCPMC13594796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.